Jessica Tassan
Stock Analyst at Piper Sandler
(1.34)
# 3,701
Out of 5,237 analysts
87
Total ratings
37.84%
Success rate
-10.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Overweight | $101 → $99 | $92.22 | +7.35% | 7 | Mar 31, 2026 | |
| CI The Cigna Group | Reiterates: Overweight | $374 → $370 | $289.07 | +28.00% | 5 | Mar 3, 2026 | |
| TDOC Teladoc Health | Reiterates: Overweight | $12 → $9 | $6.92 | +30.06% | 7 | Feb 26, 2026 | |
| DOCS Doximity | Maintains: Overweight | $40 → $42 | $26.26 | +59.94% | 6 | Feb 20, 2026 | |
| OMCL Omnicell | Reiterates: Overweight | $63 → $49 | $43.30 | +13.16% | 5 | Feb 6, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $71 → $60 | $54.74 | +9.61% | 3 | Jan 9, 2026 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $20 → $30 | $17.16 | +74.83% | 6 | Jan 6, 2026 | |
| OSCR Oscar Health | Upgrades: Overweight | $13 → $25 | $22.00 | +13.64% | 7 | Nov 26, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $423 → $417 | $384.44 | +8.47% | 9 | Oct 29, 2025 | |
| PHR Phreesia | Maintains: Overweight | $33 → $34 | $9.57 | +255.28% | 6 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $3.96 | +354.55% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.38 | +189.86% | 12 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $86 | $29.65 | +190.05% | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $288 → $272 | $274.26 | -0.82% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 → $8 | $8.15 | -1.84% | 3 | May 23, 2025 |
CVS Health
Mar 31, 2026
Maintains: Overweight
Price Target: $101 → $99
Current: $92.22
Upside: +7.35%
The Cigna Group
Mar 3, 2026
Reiterates: Overweight
Price Target: $374 → $370
Current: $289.07
Upside: +28.00%
Teladoc Health
Feb 26, 2026
Reiterates: Overweight
Price Target: $12 → $9
Current: $6.92
Upside: +30.06%
Doximity
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $26.26
Upside: +59.94%
Omnicell
Feb 6, 2026
Reiterates: Overweight
Price Target: $63 → $49
Current: $43.30
Upside: +13.16%
Hinge Health
Jan 9, 2026
Maintains: Overweight
Price Target: $71 → $60
Current: $54.74
Upside: +9.61%
Alignment Healthcare
Jan 6, 2026
Maintains: Overweight
Price Target: $20 → $30
Current: $17.16
Upside: +74.83%
Oscar Health
Nov 26, 2025
Upgrades: Overweight
Price Target: $13 → $25
Current: $22.00
Upside: +13.64%
UnitedHealth Group
Oct 29, 2025
Maintains: Overweight
Price Target: $423 → $417
Current: $384.44
Upside: +8.47%
Phreesia
Sep 5, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $9.57
Upside: +255.28%
Aug 28, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $3.96
Upside: +354.55%
Aug 27, 2025
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.38
Upside: +189.86%
Aug 15, 2025
Maintains: Overweight
Price Target: $44 → $86
Current: $29.65
Upside: +190.05%
Jul 31, 2025
Maintains: Neutral
Price Target: $288 → $272
Current: $274.26
Upside: -0.82%
May 23, 2025
Reiterates: Neutral
Price Target: $10 → $8
Current: $8.15
Upside: -1.84%